Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 8/20 | 0.54 |
| ▸ | JAK1 | P23458 | 7/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972834 | 0.91 | JAK3 (0.56) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL2474786 | 0.90 | JAK3 (0.56) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL2473715 | 0.90 | JAK3 (0.64) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL2470368 | 0.89 | NTRK1 (0.57) | CDK2CCNA2PTK2CDK1KDR | |
| SCHEMBL4973563 | 0.87 | CDK2 (0.53) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL2470647 | 0.87 | CDK2 (0.53) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL2470403 | 0.86 | CDK2 (0.53) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL4973466 | 0.85 | JAK3 (0.59) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL4973896 | 0.84 | JAK3 (0.51) | CDK2CCNA2JAK3JAK1PTK2 | |
| SCHEMBL4975331 | 0.84 | CA2 (0.55) | CDK2CCNA2JAK3JAK1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8420659-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Riger Pharmaceuticals, Inc. | 2012-11-29 | — | — | US | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.